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Available online 29 April 2014Abstract Resident cardiac stem cells in embryonic, neonatal and adult mammalian heart have been identified by different
membrane markers and transcription factors. However, despite a flurry of publications no consensus has been reached on the
identity and actual regenerative effects of the adult cardiac stem cells. Intensive research on the adult mammalian heart's
capacity for self-renewal of its muscle cell mass has led to a consensus that new cardiomyocytes (CMs) are indeed formed
throughout adult mammalian life albeit at a disputed frequency. The physiological significance of this renewal, the origin of
the new CMs, and the rate of adult CM turnover are still highly debated. Myocyte replacement, particularly after injury, was
originally attributed to differentiation of a stem cell compartment. More recently, it has been reported that CMs are mainly
replaced by the division of pre-existing post-mitotic CMs. These latter results, if confirmed, would shift the target of
regenerative therapy toward boosting mature CM cell-cycle re-entry. Despite this controversy, it is documented that the adult
endogenous c-kitpos cardiac stem cells (c-kitpos eCSCs) participate in adaptations to myocardial stress, and, when transplanted
into the myocardium, regenerate most cardiomyocytes and microvasculature lost in an infarct. Nevertheless, the in situ
myogenic potential of adult c-kitpos cardiac cells has been questioned. To revisit the regenerative potential of c-kitpos eCSCs,
we have recently employed experimental protocols of severe diffuse myocardial damage in combination with several genetic
murine models and cell transplantation approaches showing that eCSCs are necessary and sufficient for CM regeneration,
leading to complete cellular, anatomical, and functional myocardial recovery. Here we will review the available data on adult
eCSC biology and their regenerative potential placing it in the context of the different claimed mechanisms of CM replacement.
These data are in agreement with and have reinforced our view that most CMs are replaced by de novo CM formation through
the activation, myogenic commitment and specification of the eCSC cohort.
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century in the treatment of cardiovascular disease, which is
increasingly effective in dealing with the acute stages of
life-threatening pathology, they often extend the life of the
patient at the expense of generating a chronic condition.
The chronic sequels from an acute myocardial infarction
(AMI), such as chronic heart failure (CHF), are frequently
without effective treatment or leave organ transplantation
as the only alternative to restore function, with all the
logistic, economic and biological limitations associated with
this intervention (Kahan et al., 2011).
The continuous increase in average human lifespan with
progressive aging of the population in all developed countries
has generated an increasingly severe epidemic of chronic
diseases whose treatment absorbs an ever-larger fraction of
human resources and of the healthcare budget. Presently,
there are N5 million patients in CHF post-AMI in the USA
alone (Roger et al., 2012). More than 550,000 new patients
per year are added to this group, which has a similar
prevalence in the EU countries. After the first episode, CHF
post-AMI has an average annual mortality rate of ~18% and in
the USA alone absorbs N$30 billion annually for its care
(Roger et al., 2012). The root problem of CHF in general and
post-AMI in particular is a deficit of functional myocardial
contractile cells (cardiomyocytes) and adequate coronary
circulation to nurture them. This combination triggers
pathological cardiac remodelling, which, in turn, produces
further myocyte death and the late development of cardiac
failure in these patients (Jessup et al., 2003). For these
reasons, during the past decade a goal of cardiovascular
research has been to find methods to replace the cardio-
myocytes lost as a consequence of an MI and other insults in
order to prevent or reverse the pathological cardiac re-
modelling. Therefore, stem cell-based therapies have be-
come an attractive experimental treatment for heart disease
and failure (Terzic et al., 2010).
Until recently, a paucity of understanding about the
cellular homeostasis of most adult solid tissues has been a
major factor limiting the expansion to other areas ofmedicine of the early breakthroughs in adult stem cell
research and therapy, such as those applied to the blood and
bone marrow diseases. Early in the last decade the prevalent
view was that, although tissues like the bone marrow,
intestinal epithelium and skin exhibit a robust self-renewal
capacity based on the presence of adult (also called
“tissue-specific”) stem cells (Mercier et al., 2011; Simons
et al., 2011; Fuchs, 2009), they were an exception. The
established paradigm was that the majority of the remaining
solid tissues either renewed very slowly (such as the muscle
and the endothelial lining of the vascular system), with
renewal being physiologically irrelevant, or not at all. It was
firmly believed that starting shortly after birth many tissues
did not harbour functional regenerating (stem) cells. A
logical consequence of the above paradigm was the belief
that for most organs the number and function of their
parenchymal cells was in a downward spiral starting in late
infancy and continued until death. With the exception of
the three main self-renewing tissues mentioned above, it
necessarily followed that all therapeutic approaches to
disease processes caused by a deficit in the number of
functional parenchymal cells could be only directed toward
improving and/or preserving the performance of the func-
tional cells remaining in the tissue. Thus, to return the tissue
or organ to the status quo ante required the transplantation
of either identical cells from another individual or transplan-
tation of a cell type capable of differentiating into the cells
whose shortage needed to be covered. Because the cells
needed for the second option did not exist for the majority of
tissues, heterologous/allogeneic organ and cell transplanta-
tion became the only possible avenues. In fact, despite the
multiple drawbacks of heterologous cell/organ transplanta-
tion, its practice has become the cutting edge for several
medical specialties (Badylak et al., 2012). However, the
extreme shortage of donors, high costs, and the severe side
effects of immunosuppression have limited this therapy to a
small fraction of candidates in need of treatment. Thus, the
positive reception and high expectations that received the
successful derivation of multipotent human embryonic stem
cells (hESCs) (Evans et al., 1981; Thomson et al., 1998;
Murry, 2008) with the capacity to differentiate into most, if
not all, known cell types promised an unlimited supply of
617The cardiac stem cell compartmentdonor parts. When the euphoria caused by this development
started to dim, because of the ethical and immunological
challenges posed by the use of hESCs, came the breakthrough
which permitted the conversion of different adult somatic
cells, such as fibroblasts, into multipotent cells called
induced pluripotent stem (iPS) cells by introduction of a
very limited number of genes (now known to be responsible
for the multipotent state of stem cells) (Takahashi et al.,
2006; Takahashi et al., 2007) or their products. With the
development of iPS cells, it became possible to produce
different types of parenchymal cells starting with an
abundant and easy to obtain cell type from the same patient
to be treated. Once converted into the parenchymal type
needed, these could be potentially used for autologous
cell therapy (Yamanaka, 2007). Although the potential of the
iPS cells as therapeutic agents remains high, it is already
clear that many hurdles need to be cleared before they
can reach clinical application (Robinton et al., 2012). The
recent protocols to convert somatic cells directly into
some types of parenchymal cells without apparently going
through the multipotent stage by introducing tissue-specific
transcriptional factors (Qian et al., 2012; Song et al., 2012;
Jayawardena et al., 2012) might be too recent to evaluate
their clinical potential.The adult heart is a self-renewing organ
Over the past 15 years there has been a slow but steady
re-evaluation of the prevalent paradigm about adult
mammalian – including human – tissue cellular homeostasis.
It has been slowly appreciated that the parenchymal cell
population of most, if not all, adult tissues is in a continuous
process of self-renewal with cells continuously dying and
new ones being born. Once cell turnover was accepted as a
widespread phenomenon in the adult organs, it was rapidly
surmised that in order to preserve tissue mass, each organ
constituted mainly of terminally differentiated cells needed
to have a population of tissue-specific regenerating cells.
Not surprisingly, this realization was rapidly followed by the
progressive identification of stem cells in each of the adult
body tissues, even including the brain (Rountree et al., 2012;
Reule et al., 2011; Kopp et al., 2011; Kotton, 2012; Buckingham
et al., 2008; Suh et al., 2009).
Despite the change in the concept of tissue cell homeo-
stasis, the cardiovascular research community has continued
to treat the adult mammalian heart as a post-mitotic organ
without intrinsic regenerative capacity. Notwithstanding
several reports showing a yet contradictory range from
0.0005% to 3% cardiomyocyte cell cycle activity in normal
adult mammalian hearts (Rumyantsev, 1991: 3; Soonpaa et
al., 1998; Anversa and Kajstura, 1998), the prevalent view
considered the 0.0005% as the most appropriate estimate for
cardiomyocyte renewal, establishing in essence its negligent
value. The N20-fold increase in cardiac mass from birth to
adulthood and in response to different stimuli, was believed
to result exclusively from the enlargement of pre-existing
myocytes (Hunter et al., 1999; Soonpaa et al., 1998;
Laflamme at al., 2011). It was accepted that this myocyte
hypertrophy, in turn, was uniquely responsible for the initial
physiological adaptation and subsequent deterioration of
the overloaded heart. This belief has been based on twogenerally accepted but erroneous notions: a) all myocytes in
the adult heart were formed during foetal life or shortly
thereafter, became terminally differentiated and could not
be recalled into the cell cycle: therefore, all cardiac
myocytes have to be of the same chronological age as the
individual (Oh et al., 2001; Chien et al., 2002); b) the heart
has no intrinsic parenchymal regenerative capacity because
it lacks a stem/progenitor cell population able to generate
new myocytes. These concepts were extrapolated into the
dogma that from shortly after birth until death no new CM
generation was possible and any CMs lost by either wear
and tear or injury were not replaced. Thus, from puberty on
the myocardium entered an irreversible downslope with a
continuously decreasing number of myocytes. This continu-
ous loss was thought to be compensated for some time by
hypertrophy of the spared CMs which managed to maintain
myocardial mass. In this world there was neither room nor
need for endogenous regenerative cardiac biology. There-
fore, in the terminally differentiated heart, regeneration
could only be accomplished by the replacement of the lost or
damaged cardiomyocytes through transplantation of exoge-
nous differentiated CMs or with cells with the potential to
differentiate into them.
Despite published evidence that this prevalent view was
incorrect (Beltrami et al., 2001; Quaini et al., 2002; Urbanek
et al., 2003; Urbanek et al., 2005; Anversa et al., 2002;
Nadal-Ginard et al., 2003), it took the publication of
Bergmann et al., 2009, to produce a significant switch in the
prevalent opinion. This work, based on 14C dating in human
hearts concluded that during a lifetime the human heart
renews ~50% of its myocytes (Bergmann et al., 2009).
However, because this “measured” self-renewal depends on
the validity of a complex mathematical formula, whose
impact on the results dwarfs that of the measured data
which did not appear to be very robust, its physiological
significance has remained in doubt. Furthermore, their
calculations identify the highest turnover rate during youth
and early adulthood followed by a steady decrease with age.
This latter conclusion, which is contrary to most or all the
turnover values measured for all other human tissues,
including the heart (Nadal-Ginard et al., 2003), has passed
without a ripple. It is a well-documented fact that cell
death of all solid tissues increases with chronological age in
all mammal, including humans. Without replacement of
many of the lost cells, aging would irreversibly lead to the
disappearance of the tissue/organ particularly in the most
long-lived individual. Yet, the regenerative capacity of
most tissues, including the myocardium also decreases with
age and, in most cases, results in a cellular deficit because
the rate of cell loss is higher than that of regeneration
(Nadal-Ginard et al., 2003; Torella et al., 2004). Despite all
this confusing and often contradictory evidence, the adult
mammalian heart's capacity for self-renewal appears to
have finally settled with a consensus that new
cardiomyocytes (CMs) are indeed formed throughout adult
mammalian life (Hsieh et al., 2007; Bergmann et al., 2009)
Nevertheless, the physiological significance of this renew-
al, the origin of the new CMs, and the rate of adult CM
turnover are still highly debated. While Bergmann et al.,
(2009) calculated a yearly CM turnover of about 1%, others
have calculated 4-10% (Senyo et al., 2013; Malliaras et al.,
2013) and some as high as 40%/year (Kajstura et al., 2012).
Figure 1 Adult cardiomyogenesis. Adult myocardial tissue during lifespan adds new cardiomyocytes (CMs) in response to CM loss
due to different triggers like aging or ischemic/non-ischemic injury. Resident endogenous cardiac stem/progenitor cells (eCSCs) give
rise to new functional CMs. However, it has been claimed that adult CMs can actually replicate to form new CMs.
618 B. Nadal-Ginard et al.This large spread raises significant scepticism about the
validity of the methodologies used and leaves unanswered
the physiological significance of CM replacement due to
normal wear and tear in adulthood and after injury.
Whether the newly formed myocytes originate from
precursor cells or from the division of pre-existing
myocytes was not addressed (Bergmann et al., 2009)
(Fig. 1).Where does the regenerative potential of the
adult mammalian heart reside?
As discussed above, what still remains controversial is not
only the amount and physiological significance of cardio-
myocyte turnover but also the origin of the newly formed
myocytes (Laflamme et al., 2011; Kajstura et al., 2010).
Three main sources of the new myocytes have been
claimed: a) circulating progenitors, which through the
bloodstream home to the myocardium and differentiate
into myocytes (Quaini et al., 2002); b) mitotic division of
the pre-existing myocytes (Boström et al., 2010; Bersell et
al., 2009; Kühn et al., 2007; Senyo et al., 2013) and c) a
small population of resident myocardial and/or epicardial
multipotent stem cells able to differentiate into the main
cell types of the heart: myocytes, smooth and endothelial
vascular and connective tissue cells (Beltrami et al., 2003;
Torella et al., 2007; Rasmussen et al., 2011; Ellison et al.,
2013). It is clear now that the blood borne precursors,
although documented as a biological phenomenon (Quaini
et al., 2002; Eisenberg et al., 2006) might be limited to
very special situations (Orlic et al., 2001) and their direct
regenerative import is, if any, very limited (Loffredo et
al., 2011).Is re-entry of pre-existing adult cardiomyocytes
into the cell cycle responsible for myocardial
cell homeostasis and the regenerative response
to increased workload and injury?
The mammalian myocardial response to increased workload
and to injury is conditioned by the fact that, shortly after
the post-natal period, CMs permanently withdraw from the
cell cycle (Nadal-Ginard., 1978). The molecular mechanism
of terminal differentiation in CMs has not yet been
completely defined. Different experimental models indicate
that cardiac muscle lineage determination genes directly
interact with the retinoblastoma (Rb) pocket proteins to
produce and maintain the terminally differentiated state
(Tam et al., 1995; MacLellan et al., 2005). After more than 3
decades of research, there are literally hundreds of papers
in reputed journals documenting that mature myocytes in
and from the adult myocardium do not re-enter the cell
cycle and in the very rare occasions they do, do not undergo
mitosis but apoptose, at least in part, due to a deficit in
centriole formation (Schneider et al., 1994). This block of
cell division (which does not necessarily blocks bi-nucleation
and DNA endo-reduplication) has been shown both in vivo
and in vitro in different mammalian species from mouse to
human. This behaviour is in contraposition to the replication
capacity of foetal and neonatal mammalian myocytes, which
do not yet express pRB, and in the mouse can extend up to
7–8 days post-natally (Porrello et al., 2011) as well as those
of adult invertebrates, fishes and reptiles (Kikuchi et al.,
2012). Furthermore, adult mammalian myocytes can also be
co-axed to re-enter the cell cycle at a significant rate
through genetic manipulations at the expense of the
stability of their differentiated function (MacLellan et al.,
2005). Notwithstanding the elegant studies documenting
619The cardiac stem cell compartmentthat adult cardiomyocytes divide in species other than
mammals (Zhang et al., 2013), these findings cannot and
should not be extrapolated to the adult mammalian heart.
Despite the overwhelming observational and experimen-
tal evidence summarized above, a provocative recent
publication by Senyo et al., (2013) claimed that adult
myocyte renewal is mostly accomplished by division of
pre-existing cardiomyocytes, which was estimated to be a
more relevant source than resident (or circulating) stem/
progenitor cells. Indeed, the authors stated that the birth of
cardiomyocytes from pre-existing cardiomyocytes has aFigure 2 Z/EG×MYH6-MerCreMer mice for adult cardiomyocyte pe
MYH6-MerCreMEr mice to obtain double transgenic mice with tam
Tamoxifen administration, at the most, GFP-labels 80% of the adu
β-galactosidase (β-Gal). Either Isoproterenol injury or myocardial
increased percentage of β-Galpos myocytes, which indirectly shows n
eCSCs). BrdU labelling in these mice after the initial injury marks
myocyte formation in response to myocyte loss is accomplished by n
*adapted from Ellison et al. Cell. 2013; 154:827–42.projected rate of roughly 0.76% per year in the young adult
mouse under normal homeostatic conditions, a rate that
increases after myocardial injury in the border region. Also
the authors interpreted their findings as a demonstration
that cardiac progenitors do not have a significant function in
myocardial homeostasis in mammals and thus their role after
injury is also limited (Senyo et al., 2013). This publication
has been taken by some as a demonstration of the negligible
or secondary role of resident CSCs in adult mammalian
myocardium homeostasis and regeneration. Interestingly,
two previous publications from the same laboratory on thermanent labelling. The cartoon shows the breeding of Z/EG and
oxifen-inducible GFP labelling of adult cardiomyocytes (CMs).
lt CMs leaving 20% of them un-recombined and still expressing
infarction in these mice cause GFPpos CM dilution in favour of
ew CM formation from non-myocyte cells (that we show to be the
mainly/only β-Galpos myocytes, which further shows that new
on-myocyte cells (i.e. eCSCs).
620 B. Nadal-Ginard et al.same topic and using the same experimental animal
models (Hsieh et al., 2007; Loffredo et al., 2011), reached
exactly the opposite conclusions; that is, new CMs
originated not from pre-existing CMs but from a stem cell
population which they did not identify. Additionally,
Marban's group using the same genetic cell fate tracking
mouse model, concluded that CM renewal after AMI is
accomplished by both pre-existing CM division and resident
stem cell differentiation, with a higher contribution by the
latter which is further amplified by cardiosphere-derived
cell therapy (Malliaras et al., 2013). In contrast, we have
reported that the resident stem cells are not only
necessary but sufficient for full myocardial regeneration
after diffuse and segmental damage and we have also ruled
out any meaningful contribution of mature CM division
(Ellison et al., 2013).
The contradictory results pointed out above are, at least
in part, due to a misconception of the strength of the
transgenicmousemodels used for the test. The so-called Z/EG
mouse is a double-reporter mouse line that switches from
expressing lacZ to enhanced green fluorescent protein (eGFP)
in the targeted cells upon Cre-mediated excision (Hsieh et al.,
2007) (Fig. 2). Although powerful and useful, this mouse is not
fully effective when applied to the genetic labelling of adult
CMs by cross-breeding Z/EG with α-MHC-MerCreMer mice
where Cre is expressed under the control of MYH6 (α-MHC)
promoter. Its main drawback is that when the MerCreMer
construct is induced by Tamoxifen, only ~80% of the
cardiomyocytes recombine the floxed transgene and turn on
the eGFPmarker (Hsieh et al., 2007). Therefore, one of every 5
cells continues to express the constitutive transgene,
β-galactosidase, and their origin cannot be ascertained (Hsieh
et al., 2007). For this reason, new CM formation has to be
quantified indirectly by the “dilution” of the eGFP positive
myocytes by the new myocytes, which, because they did not
exist at the time of tamoxifen induction, should express the
constitutive β-galactosidase reporter. Because all numbers are
relative, the formation of new β-galactosidase-expressing
myocytes by necessity leads to an increase of the % of
β-galactosidase (β-Gal)-expressing cells and the corresponding
decrease in the % of the eGFP-expressing cohort. This indirect
measurement reduces the sensitivity and accuracy of the test,
particularly if the number of newly formed myocytes is small.
On the other hand, a major advantage of this alternative
double-reporter genetic model is to provide a clear-cut
qualitative answer as to whether new CMs are formed after
injury and if so, whether these new CMs originated
predominantly from pre-existing CMs or from another cell
population. If no new CMs are formed after the tamoxifen
induction, the relative ratio eGFP/β-Gal (80/20) should
remain constant. However, this eGFP/β-Gal ratio changed
from 80/20 to 65/35 after myocardial injury (Hsieh et al.,
2007), which indicates a robust formation of new CMs. The
genetic labelling and fate tracing by the double transgenic
mouse proves that the majority, if not all, new myocytes
after injury have been formed by non-pre-existing CMs (or
more precisely by cells that were not expressing the α-MHC
gene during the Tamoxifen induction of the MerCreMer
construct). Thus, these results should have settled the
question of whether new CMs are formed after damage from
a source other than pre-existing CMs. Yet, it does not
exclude that some could have originated from pre-existingCMs and also does not provide information about the “cell
cohort” most new CMs originated from.
It follows that, in this transgenic setup identifying a small
(negligible?) level of incorporation of a DNA-labelling com-
pound in a few eGFP (in the range of b0.1%) but not in the
β-Gal positive cardiomyocytes, as reported by Senyo et al.
(2013) it is not sufficient to conclude that adult pre-existing
cardiomyocytes can actually divide, because it pushes this
DNA-labelling tool beyond its power and sensitivity. In fact,
the more sensitive the method of detecting DNA labelling the
less reliable becomes its interpretation. The cumulative error
of this approach is reported by the authors to be 0.2% (Hsieh et
al., 2007) and, therefore, far larger than the measured values
(b0.1%) (Senyo et al., 2013). Furthermore, it is assumed that
the eCSCs in their quiescent state do not express any
detectable level of α-MHC (Myh6), so that it could be argued
that no CSC-derived myocyte would turn on eGFP expression
as result of α-MHC-regulated cre-lox recombination induced
by tamoxifen. Unfortunately, the reality is different. We have
shown that the eCSCs robustly and rapidly commit to myocyte
lineage and induce the expression of myocyte-specific genes
after damage (Ellison et al., 2013). This fact suggests that cre
induction by administration of Tamoxifen over a two
week-long period can induce the β-Gal to eGFP recombination
in those eCSCs that have activated expression of the Myh6
gene after committing to the myocyte lineage (Ellison et al.,
2013). In agreement with the above conclusion, it has been
reported recently that myocardial injury activates the
α-MHC-MerCreMer transgene in c-kitpos cardiac progenitors
(Dong et al., 2012).
In the first paper using the above-described genetic model,
Lee's group (Hsieh et al., 2007) reported that after myocardial
infarction or pressure overload, the percentage of eGFP+
cardiomyocytes decreases from 82.8% in the sham-treated
mice to 67.5% in areas bordering a myocardial infarction,
indicating that stem cells or precursor cells had replenished the
cardiomyocytes. Thus, in the MI border zone 15.3% of the
myocytes are new and have been formed after the damage.
The authors excluded division of the existent myocytes as main
contributors to the myocyte “refreshment”. Indeed, most
BrdU+ cardiomyocytes were GFP-negative and, therefore,
could not be derived from the majority of pre-existing
myocytes. Although some BrdU+/Troponin-T+/GFP+ were
present in the border zone (none in the remote zone) after
myocardial infarction their frequency, 0.07%, is significantly
below the reported leakage of the genetic system, i.e. 0.2%
and cannot be distinguished from background. However, even
if 0.07% of the new myocytes had originated from pre-existing
myocytes (BrdU+/Troponin-T+/GFP+) it still leaves 15.1%,
which have originated from cells, which had not expressed Cre
during the tamoxifen induction and, therefore, as the authors
conclude, originated from a population of myocardial stem/
precursor cells. A following paper from the same laboratory
(Loffredo et al., 2011), using the same double transgenic
mouse model, concludes that cell therapy with bone
marrow-derived c-kit+ cells after myocardial infarction
further dilutes the GFP+ pool (56.6% vs. 68.8%). A result that
is consistent with transplanted c-kitpos cell-mediated
augmentation of cardiomyocyte progenitor activity.
The only difference between the study of Senyo et al.
(2013) concluding that new myocytes originate from the
division of pre-existing ones and the previous two papers from
621The cardiac stem cell compartmentthe same laboratory that concluded that new myocytes after
myocardial damage originated not from the pre-existing
myocytes but from a pool of stem/precursor cells, is that in
the latest publication, instead of using BrdU labelling to
identify new myocytes, stable isotope labelling followed by
multi-isotope imaging mass spectrometry (MIMS), was used,
which appears to be able to localize stable isotope reporters in
domains smaller than 1 μm3. Using this technique, the authors
affirm that an important response to myocardial injury is new
myocyte production originated from the pre-existing mature
myocytes in the infarct/border. This statement is based on
finding a total of 6 analogue-labelled nuclei out of 4190
myocytes analysed in the normal adult heart, which are
diploid, mononucleated and GFP+. That is, 6/4190 = 0.0014%
have originated from pre-existing myocytes in the normal
heart. The situation is not more convincing in the myocardial
infarction where a total of 11 individual nuclei are identified inFigure 3 Resident endogenous cardiac stem/progenitor cells (eC
CD45neg sorted eCSCs from a wild type adult mouse heart is charac
eCSCs is the ability to grow in non-adherent culture conditions
representative confocal image shows a typical cardiosphere derived f
differentiation potential into cardiomyocyte (CM), smooth muscle c
*panels A and B adapted from Ellison et al. Cell. 2013; 154:827–42.the border area, which the authors argue originated from
pre-existing myocytes. However, 12% of the putative new
myocytes in the same region are not originated from
pre-existing myocytes (67% after AMI vs. 79% in control mice
GFP+ myocytes). So, even taking their data at face value, 11/
7063 = 0.0015% new myocytes are coming from pre-existing
myocytes, while 12% originated not from adult myocytes.
The above review summarized the available evidence
claiming a major role of pre-existing myocyte replication
over eCSC activation followed by myogenic specification as
the source of the regenerated myocytes in myocardial cell
homeostasis and regeneration after damage. We argue that
when analysed closely these reports, taken together and
individually, do not support the conclusions of Senyo et al.
(2013) but argue against them. In fact, the data do not
contradict the main tenets of accepted myocardial cell
biology but instead support the main role of eCSC in cardiacSCs). (A) Essential CD membrane-phenotypic profile of c-kitpos
terized by FACS analysis. (B) One of the main properties of the
as pseudo-embryonic bodies, named cardiospheres (CS). The
rom a cloned rat eCSC. (C) Cartoon schematics of CSC tri-lineage
ell (SMC) and endothelial cell (EC).
622 B. Nadal-Ginard et al.cell homeostasis and regeneration in the adult mammalian
heart. Furthermore, it is a well-documented fact that newly
formed CMs are not yet terminally differentiated and are
capable of a few rounds of mitosis before irreversibly
withdrawing from the cell cycle (Nadal-Ginard et al., 2003).1 These postulates state that a causal agent must: (a) be present in
every case of the disease/phenomenon; (b) be isolated from the
disease host and grown in vitro; (c) the disease/phenomenon must
be reproduced when the agent is delivered to a susceptible host;
and (d) be recovered from the transmitted host.The eCSCs are necessary and sufficient for
adult myocardium cellular homeostasis as well
as functional and anatomical repair after
major damage
Undoubtedly, the best documented source of regenerating
myocardial cells in the adult mammalian heart, including the
human, is a small population of cells distributed throughout
the atria and ventricles of the young, adult and senescent
mammalian myocardium, that have the phenotype, behav-
iour and regenerative potential of bona fide endogenous
cardiac stem cells (eCSCs) (Fig. 3) (Torella et al., 2007;
Rasmussen et al., 2011; Srivastava et al., 2006; Ellison et al.,
2013). The first report of these endogenous regenerating
myocardial stem cells was in 2003 (Beltrami et al., 2003).
Shortly thereafter, several stem/progenitor cell types were
identified in the adult mammalian heart by different
membrane markers and transcription factors (which often
led to claims of a new stem cell type with each new marker
used for its identification). Indeed, when referring to eCSCs
or cardiac progenitor cells (CPCs), there are at least seven
resident heart populations so far identified (mainly accord-
ing to the single antigen used for their primary isolation) in
the adult mammalian heart, including the human (Ellison et
al., 2013). These are c-kitpos eCSCs (that have been also
defined as CD34neg, CD45neg, Sca-1pos, Abcg2pos, CD105pos,
CD166pos, GATA4pos, NKX2-5low, MEF2Cpos) (Beltrami et al.,
2003; Ellison et al., 2013); Sca1pos eCSCs (CD34neg, CD45neg,
FLK1neg, c-kitlow, GATA4pos, NKX2-5low, MEF2Cpos) (Oh et al.,
2003; Matsuura et al., 2004); side population (SP) cells
(CD34pos, CD45pos, Abcg2pos, Sca1pos, c-kitpos, NKX2-5neg,
GATA4neg) (Martin et al., 2004); Cardiosphere-derived cells
(CD105pos, CD34pos, CD45pos, Abcg2pos, Sca1pos, c-kitlow)
(Messina et al., 2004; Smith et al., 2007; cardiac resident
colony-forming unit-fibroblast (cCFU-Fs) (Sca-1pos,
PDGFRαpos, CD31neg, c-kitlow, CD45neg, FLK1neg, CD44pos,
CD90pos, CD29pos, and CD105pos) (Chong et al., 2011);
cardiac mesangioblasts (CD31pos, CD34pos, CD44pos,
CD45neg, Sca1pos, c-kitpos) (Sampoalesi et al., 2005); and
the Isl-1pos cardiac progenitor cells (CPCs) (CD31neg, Sca1neg,
ckitneg, GATA4pos, NKX2.5pos) (Laugwitz et al., 2005; Moretti
et al., 2006). Another multipotent cell type, present in the
epicardium has been described (Smart et al., 2011).
All these claims led to the paradoxical situation whereby
the heart, previously described as a non-renewing organ, has
turned into the organ with the highest number of distinct
types of resident stem/progenitor cells. However, aside
from the Isl-1pos cardiac progenitor cells, which are direct
progeny of a defined embryonic cardiac progenitor cell
population present in only very small numbers in the adult
heart (Laugwitz et al., 2005), and the epicardial stem/
progenitor cell, which seem originated in the proepicardial
organ (Smart et al., 2011), it is evident just from the
significant overlap of the main and secondary markers usedfor their characterization that the different eCSC/CPC
populations are closely related. So it is logical to postulate
that many, if not all, different putative adult eCSCs reported
so far, likely represent different developmental and/or
physiological stages of a unique resident stem-progenitor
cell type with multipotent regenerative capacity yet to be
completely defined (Ellison et al., 2010). Clearly, cell
lineage tracking in genetically modified mice, if properly
designed, would be an invaluable tool to try to establish the
connection among the different eCSC/CPC populations as
well as their real contribution to heart development, adult
homeostasis and disease.
The progeny of a single eCSC is able to differentiate in
vitro and in vivo into cardiac myocytes, smooth muscle and
endothelial vascular cells and when transplanted into the
border zone of an infarct or into a myocardium with severe
diffuse damage, they regenerate functional contractile
muscle, the microvasculature and the connective tissue
(Beltrami et al., 2003; Ellison et al., 2013) leaving the
myocardium with an anatomical, cellular and molecular
phenotype indistinguishable from the spared myocyte cohort
(Ellison et al., 2013). In a normal adult myocardium, at any
given time, most of the eCSCs are quiescent and only a small
fraction is active to replace myocytes and vascular cells lost
by wear and tear. In response to stress (hypoxia, exercise,
work overload, or other damage), however, a proportion of
the resident eCSCs are rapidly activated, multiply and
generate new muscle and vascular cells (Ellison et al.,
2007b; Waring et al., 2012; Ellison et al., 2012) contributing
to cardiac remodelling. CSC transplantation can regenerate
the contractile cells lost as a consequence of a major AMI
affecting up to 25% of the left ventricular mass (Beltrami et
al., 2003; Ellison et al., 2013).
The identification of multiple putative cardiac stem cells
types raises the question of whether any of them is primarily
responsible for the cellular homeostasis of the myocardium
throughout life and its repair in response to damage. Koch's
postulates,1 enunciated in 1884 for infectious agents, have
been lately used as general criteria to establish that a
specific entity is the causative agent of a particular disease
or biological phenomenon (Brown et al., 1992; Chien at al.,
2000) Despite these postulates being formulated in a
scientific environment vastly different from the present,
they are still a powerful tool to test a cause-effect
relationship between two phenomena (Brown et al., 1992;
Chien at al., 2000).
In order to test whether the scepticism towards resident
cardiac stem/progenitor cells is justified or whether, on the
contrary, adult c-kitpos eCSCs fulfil Koch's postulates as
causal agents for cardiac homeostasis and regeneration, we
employed experimental protocols of severe diffuse myocar-
dial damage with preserved coronary circulation which,
unlike an experimental infarct with permanent coronary
ligation, spares the eCSCs (Ellison et al., 2007a). This model
was used in several transgenic mice and in combination with
Figure 4 eCSCs are necessary and sufficient for myocardial regeneration. The cartoon depicts cardiac regenerative response
following Isoproterenol (ISO) injury. (A)ISO acutely induces cardiomyocyte (CM) death and left ventricular dysfunction, which is
followed by CM hypertrophy and endogenous c-kitpos cardiac stem/progenitor cell activation with new CM formation and
normalization of cardiac function. (B) When eCSCs are ablated by 5-FU treatment after ISO injury, no new myocytes are generated
and the heart goes into chronic heart failure. (C) When rats with failing hearts by ISO+5-FU damage are treated with injection of GFP
labeled CSCs carrying the suicide gene TK (CSCGFP/TK), myocyte regeneration is restored with recovery of cardiac dysfunction. Finally,
if the injected CSCs and their progeny are induced to suicide by Ganciclovir treatment, the heart sets back again to failure.
623The cardiac stem cell compartmentcell transplantation approaches. These tests have shown
that the eCSCs autonomously repair extensive cardiac
diffuse damage, leading to complete cellular, anatomical
and functional cardiac recovery (Ellison et al., 2013).
Furthermore: a) If the eCSCs are ablated, myocardial
regeneration is stunted causing heart failure unless they
are replaced by exogenous CSCs; b) Selective suicide of
these exogenous “replacement” CSCs and their progeny
abolishes regeneration and severely impairs ventricular
performance; c) The transplanted CSCs can be recovered
from the recipient retaining their original characteristicsand d) maintain their original regenerative potential when
re-transplanted into a new recipient. Therefore, these data
confirmed that eCSCs fulfil all Koch's postulates as the cell
type necessary and sufficient for myocardial repair and
regeneration (Fig. 4).
These conclusions rest mainly on three experimental
facts: a model of myocardial injury with patent coronary
circulation to test the spontaneous regenerative capacity of
eCSCs; in situ labelling and genetic tracking the fate of c-kit
positive cardiac stem cells and the replacement of the eCSCs
by transplantation of genetically tagged CSCs (Ellison et al.,
624 B. Nadal-Ginard et al.2013). To that effect, we endeavoured to exclude most of the
challenges posed by the potential pitfalls arising from the
employed experimental tools. In particular, we demonstrated
that newly formed BrdU positive myocytes originate from
endogenous and also transplanted CSCs employing multiple and
complementary approaches, like genetic tracing, FACS sorting,
cell and tissue immunofluorescence, confocal microscopy
analysis, and genome pattern of expression. The specificity of
the c-kit/cre lentiviral construct to recombine only c-kit
expressing cardiac cell lineages in R26/floxed-stop-YFP trans-
genic mice was demonstrated in vitro and in vivo by cyto/
histo-chemistry, FACS and RT-PCR. The effect of 5-fluoro-uracil
(5-FU) and Ganciclovir regime for CSC ablation on neighbouring
cells and the essential role of resident CSCs in myocardial
regeneration were assessed again by multiple assays. Briefly,
the replacement of the endogenous CSCs with cloned geneti-
cally labelled CSCs, lead to full anatomical and functional
recovery of the transplanted animals while the control cohort
(untreated or treatedwith cardiac fibroblasts) developed lethal
heart failure. When the transplanted cells were induced to
suicide by Ganciclovir treatment the animals were set back in
heart failure. The so-called “bystander effect” elicited by
Ganciclovir and cell suicide was ruled out with the best
obtainable evidence in vitro and in vivo. In addition, these
transplanted cells were isolated from the transplanted hosts
and proven to maintain their CSC properties in vitro and in a
second round of transplantations.
We documented that 5-FU administration killed most, if
not all, the proliferating myocardial cells after ISO injury. It
logically follows that the other cardiac progenitor cell
populations were most probably also ablated by the ISO+
5-FU regimen. However, the clone of a single c-kitpos CSC
was able to rescue the failing heart phenotype. Myocardial
tissue histology and function became dependent on the
transplanted cells, which were selectively killed by
Glanciclovir. The latter does not exclude a role and
participation of the other described stem/progenitor cells
in the recovery process. It remains to be proven whether any
of the other stem/progenitor cells described so far are
equivalent and indistinguishable from c-kitpos CSCs. We
would not be surprised if actually the latter hypothesis
turn to be at least partially correct as it would reinforce our
view that the majority cardiac stem/progenitor cell are
different phenotypes of a unique tissue-specific stem/cell
population, at least based on the way they have been
characterized so far.
Concurrently, a very elegant and well-controlled study by
Braun’s group, using a triple transgenic mouse approach, has
recently lineage traced cardiomyocyte formation in the
adult life to be, at least in part, the progeny of eCSCs,
expressing Sca-1 (a fraction of which express, as above
described, also c-kit) (Uchida et al., 2013). Thus, these data
document that the adult heart has a robust autonomous
regenerative capacity, which mainly resides in the eCSCs.
This capacity, however, spontaneously is not sufficient to
significantly repair segmental tissue loses such as in AMIs
produced by occlusion of a main coronary artery. This
regeneration deficit also affects the segmental loses of any
other tissues, no matter the abundance and potency of their
tissue stem cells. The challenge is to manipulate the eCSCs
and improve their regenerative potential in order to produce
an autologous replacement of the cells lost by the insult.Stimulation of the myocardial endogenous
regenerative capacity for damage repairMost severe cardiac diseases are due to a deficit of
contractile cells, the myocytes, in number, function or
both. Therefore, most approaches to repair myocardial
damage are designed to replace the lost or dysfunctional
myocytes. It is surprising that despite the advances of the
past decade in understanding myocardial biology in general
and cardiomyocyte biogenesis in particular, their impact on
the therapeutic attempts to regenerate these losses has
been practically nil. Most reported as well as planed clinical
trials for cell-based cardiac regeneration remain focused on
the formation of new CMs by transplantation of different
non-cardiac cell types, mainly bone marrow mononuclear
cells and mesenchymal stem cells (Dauwe et al., 2011). This
behaviour remains grounded on the concept that the
regenerative capacity of the adult heart is negligible. In
this intellectual environment it is not surprising that the
cardiovascular field has fully embraced the potential of ESCs
and iPSs in cardiovascular regenerative medicine (Murry et
al., 2008; Yoshida et al., 2010). Unfortunately, the human
use of these multipotent cells remains far in the future and
faces many hurdles, which they might or might not be able
to clear. Curiously, this is happening at the time when the
regenerative potential of the endogenous CSCs has been
documented at the experimental (Beltrami et al., 2003;
Ellison et al., 2013) levels and with very promising but yet
preliminary clinical results (Bolli et al., 2011; Makkar et al.,
2012).
One potential mechanism of action of transplanting differ-
ent cell types is a paracrine activation of survival pathways in
the cells at risk in the damaged area together with the
activation of the endogenous regeneration compartment, the
eCSCs. This probable mode of action implies that the sooner
after myocardial damage the therapy is applied, the higher the
probability to save host cells at risk. Surprisingly, most
protocols apply the therapeutic cells 4 to 7 days after damaged
whenmost cells at risk are no longer recoverable (Dauwe et al.,
2011). An additional corollary of the paracrine hypothesis is
that the identification of the molecules secreted by the
transplanted cells should make possible the design of
therapies, which eliminate the use of cells and concentrate
on the administration of the principal effector molecules
produced by them. Interestingly, Smart et al. (2011) found
that ‘priming’ with thymosin β4 (Tβ4) followed by MI in
mice resulted in significant activation of Wt1+ epicardial
progenitor cells in the infarct and border regions and their
subsequent differentiation into cardiomyocytes, albeit at a
low level (b1%) relative to the activated progenitor
population as a whole (Smart et al., 2011). Therefore,
there is urgent need to identify more efficacious factors to
induce optimal eCSC activation and drive significant
regeneration and maturation of the new myocardium. This
point of view is reinforced by the demonstration that tissue
stem cells survive long periods of ischemia/hypo-anoxia
after all the differentiated cells of the tissue have died
(Latil et al., 2012).
Myocardial regenerative cell-free therapies effective on
the in situ activation, multiplication and differentiation of
the resident eCSCs would have many advantages over those
625The cardiac stem cell compartmentbased on cell transplantation. First, therapeutic components
should be available ‘off-the-shelf’ and ready to use at all
times without the lag time of many cell therapy approaches;
second, they would be affordable, in terms of production
costs of the medicinal product; third, such therapy would be
easier to apply and compatible with current clinical standard
of care for AMI, including the widespread use of percutane-
ous coronary interventions (PCI); and fourth, if the regener-
ative response produced were robust enough, it should be
able to save and/or regenerate ~50–60 g of functional
myocardial tissue, which is the minimum needed to change
the course of the disease in a seriously ill patient. Meeting
these conditions should make possible the production of a
myocardial regenerative therapy which is: a) available at all
times and to all candidate patients; b) safe and of easy
application in most medical centres; c) affordable to the
national health care systems; and d) effective in reducing
pathological cardiac remodelling and its late consequence,
chronic heart failure.Myocardial regeneration without cell transplantation:
using growth factors to stimulate the growth and
differentiation of the eCSCs
Testing regenerative therapies in mouse models of human
diseases, although a necessary step in pre-clinical assays is
not an accurate predictor of human effectiveness. This is soFigure 5 IGF-1/HGF intracoronary injection after AMI in pi
cardiomyocytes. (A) A cluster of endogenous c-kitpos CSCs in the inf
c-kitpos endogenous CSCs (B) and c-kitposNkx2.5pos myocyte progenit
regions of IGF-1/HGF-treated and control (CTRL) pigs. (D–E) Newly
border (D) and infarct (E) zone after IGF-1/HGF administration
significantly increased following IGF-1/HGF administration. All data
and 4×, respectively. *p b 0.05 vs. CTRL; †p b 0.05 vs. IGF-1/HGF 1
*adapted from Ellison et al. JACC 2011; 58:977–986.not only because of biological differences between the two
species but because of the three order of magnitude
difference in mass between the two organisms, which make
the challenges not only quantitatively but qualitatively
different. Sparing or regenerating a few mgs of myocardium
in the mouse has a significant impact in cardiac function and
survival. As mentioned above, to obtain similar effect in a
human with a moderate AMI would require the sparing and/or
regeneration of 50–60 g of tissue. Therefore, it is necessary
that pre-clinical testing of therapies be carried out in amodel,
which is more similar in tissue biology, size and physiology to
the human than the rodent models commonly used.
The pig, because of its size, rapid growth rate,
well-known physiology and availability, has proven a very
useful and frequently used pre-clinical large animal model
for different pathologies, particularly those involving tissue
regeneration. We have tested the regenerative effects of
intracoronary administration of two growth factors known
to be involved in the paracrine effect of transplanted cells
(Ellison et al., 2011). Insulin-like growth factor I (IGF-1) and
hepatocyte growth factor (HGF), in a single dose ranging
from 0.5 to 2 μg HGF and 2 to 8 μg IGF-1, intracoronary
administered just below the site of left anterior descendent
occlusion, 30 min after AMI during coronary reperfusion in
the pig. This growth factor cocktail triggers a regenerative
response from the c-kitpos eCSCs, which is potent,
self-sustained and able to produce anatomical, histological
and physiological significant regeneration of the damagedgs activates endogenous c-kitpos CSCs, giving rise to new
arct zone of an IGF-1/HGF-treated pig heart. (B–C) Number of
or cells (C) in the border (white bars) and infarcted (black bars)
formed small BrdUpos myocytes (red, α-sarcomeric actin) in the
. (F) The number of newly formed BrdUpos cardiomyocytes
are mean ± SD; n = 5, 4, 5, and 4 for CTRL, IGF-1/HGF 1×, 2×,
×; ‡p b 0.05 vs. IGF-1/HGF 2x.
626 B. Nadal-Ginard et al.myocardium without the need for cell transplantation
(Fig. 5) (Ellison et al., 2011). IGF-1 and HGF induced eCSC
migration, proliferation and functional cardiomyogenic and
microvasculature differentiation. Furthermore, IGF-1/HGF,
in a dose-dependent manner, improved cardiomyocyte
survival, reduced fibrosis and cardiomyocyte reactive
hypertrophy. Interestingly, the effect of a single adminis-
tration of IGF-1/HGF is still measurable 2 months after its
application, because a feedback loop triggered by the
external stimuli activates the production of growth and
survival factors by the targeted cells. The histological
changes were correlated with a reduced infarct size and
an improved ventricular segmental contractility and ejec-
tion fraction at the end of the follow-up as assessed by cMRI
(Ellison et al., 2011). Similar positive effects were obtained
when the HGF-IGF1 combination was administered
trans-endocardially in pigs with a chronic MI using the
NOGA system (Koudstaal et al., 2014).
Despite its effectiveness, the administration of IGF-1/HGF
has a significant drawback. Although very effective in
regenerating the CMs and micro-vessels lost, the rate of
maturation of the newly formed CMs is heterogeneous and
slow. Thus, although the CMs and microvasculature lost in the
AMI are recovered in the first three weeks, the myocardial
mass remains significantly deficient. While the newly formed
CMs in contact with spared ones mature rapidly and can reach
a diameter close to a normal pig CM, there is an inverse
correlation between new myocytes size and their distance
from the small islands of spared myocardium scattered within
the ischemic zone (Ellison et al., 2011). With the exception of
the new CMs in close proximity to spared micro-islands
surviving within the ischemic area or those in the border
region, at three weeks after treatment the length and
diameter of the remaining new CMs (~85% of those regener-
ated) is between 1/2 and 1/5, respectively, of an adult CM,
which means that their volume is significantly less than 1/10th
of their mature counterparts (Ellison et al., 2011). Because of
this slow maturation process the myocardial generation force
capacity, which is the meaningful functional recovery, also
lags behind the regeneration of the cell numbers to the
pre-AMI state. Aminimumof threemonths are required for the
regenerated myocytes to reach maturity and size comparable
to the spared ones (Ellison et al., 2013). Despite the beneficial
effect of the therapy in reducing the scar area, pathological
remodelling and partial recovery of ventricular function,
there is little doubt that it would be desirable to obtain a
more rapid recovery of the ventricular mass and the capacity
to generate force.Myocardial regeneration after allogeneic stem
cell therapyAll the currently proposed and tested autologous cell
therapies are very attractive as proof-of-concept and from
a biological standpoint. For rare diseases with chronic and
long term evolution affecting hundreds or even thousands of
patients to be treated, these personalized therapies,
despite their high cost in medical and material resources,
might make sense from an economic and health care
standpoint. Unfortunately, this is not the case for diseasesof high prevalence, such as the sequels of ischaemic heart
disease, with millions of patient candidates for regenerative
therapy. Not even the richest societies have the resources
needed to support a programme of personalized regenera-
tive medicine for the patients already in CHF who presently
are left with heart transplantation as the only realistic
option for recovery. Therefore, although autologous cell
transplantation therapies have produced some encouraging
preliminary results in the clinic with the potential of
improving a narrow subset of patients, we believe that all
of the autologous cell strategies taken together, now and in
the foreseeable future, are and will continue to be incapable
to favourably impact the societal health care problem posed
by the consequences of CHF post-AMI.
Moreover, as outlined above, a consensus is gaining
ground that most of the favourable effects of cell transplan-
tation protocols used until now exert their beneficial effect
by a paracrine mechanism of the transplanted cells over the
surviving myocardial cells at risk and/or through the
activation of the endogenous myocardial regenerative
capacity represented by the eCSCs (Gnecchi et al., 2008;
Hatzistergos et al., 2010). If this is correct, then there seems
to be little advantage in the use of autologous cells because
a similar, and perhaps enhanced, effect can be obtained by
the administration of the proper growth factors, the
appropriate cell type isolated from allogeneic sources or a
combination of both. Allogeneic cells can be produced in
large quantities beforehand, stored frozen before their use
and made available at all times. That would allow their use
not only for the treatment of the pathological remodelling
once it has developed but soon after the acute insult to
prevent or diminish the pathological remodelling.
Unresolved clinical questions related to the use of
allogeneic stem cells in the treatment of patients with AMI
remain the identification of the optimal cell population and
also the method(s) and time of administration. As previously
stated, to be widely available and compatible with current
clinical standard of care for AMI, an intracoronary method for
delivery at the time of the primary revascularization is the
most feasible. Also, direct myocardial injection during
revascularization surgery is highly realistic. Mesenchymal
stem cells (MSC) have a broad repertoire of secreted trophic
and immunodulatory cytokines, however they also secrete
factors that negatively modulate CM apoptosis, inflammation,
scar formation and pathological remodelling (Ranganath et
al., 2012). Moreover, it is questionable whether they are the
optimal cell to use in terms of survival and homing to and
engraftment in the myocardium since only ~3–4% of the cells
administered intracoronary are retained in the myocardium
(Dauwe et al., 2011). Furthermore, MSCs can be large and
become entrapped in the microvasculature and impede their
entry into the myocardium.
Recently, Marban et al. (Malliaras et al., 2012) have
tested the safety and efficacy of using allogeneic, mis-
matched Cardiosphere-Derived Cells (CDCs) in infarcted
rats. Allogeneic CDC transplantation resulted in a robust
improvement of fractional area change (~12%), ejection
fraction (~20%), and fractional shortening (~10%), which
was sustained for at least 6 months. Furthermore, alloge-
neic CDCs stimulated endogenous regenerative mechanisms
(recruitment of c-kitpos eCSCs, angiogenesis) and increased
myocardial VEGF, IGF-1 and HGF.
627The cardiac stem cell compartmentWe have previously shown that eCSCs that express high
levels of the transcription factor GATA-4 exert a paracrine
survival effect on CMs through increased IGF-1 secretion and
induction of the IGF-1R signalling pathway (Kawaguchi et al.,
2010). Furthermore, unlike other cell types (Abdel-Latif et
al., 2007; Hofmann et al., 2005), CSCs have a very high
tropism for the myocardium. When administered through the
systemic circulation the majority of CSCs home and nest into
the damaged myocardium (Ellison et al., 2013). Under
proper culture conditions it is possible to clone and expand
a single rodent, porcine or human eCSC to up to 1x1011 cells
without detectable alteration of karyotype, loss of differ-
entiating properties or the phenotype of the differentiated
progeny (Ellison et al., 2011). These cloned cells produce a
repertoire of pro-survival, anti-inflammatory and cardiovas-
cular regenerative growth factors such as: IGF-1, HGF, TGF-β1
superfamily, including activins and BMPs, neuregulin-1,
periostin, and BMP-10 among others (Waring et al., 2012).
For this reason, we decided to test whether these cloned and
in vitro expanded cells, when administered into allogeneic
animals, would be the source of a more complex and
physiologic mixture of growth and differentiating factors
which, through a paracrine effect, would produce a robust
activation of the eCSCs with more rapid maturation of their
progeny. It was expected that once their short-term effect
had been produced and the auto/paracrine feedback loop of
growth factor production has been activated in the eCSCs, the
allogeneic cells would be eliminated (presumably by apopto-
sis) and that the regeneration triggered by activated eCSCs
would be completely autologous. c-kitpos eCSCs do not expressFigure 6 Activation of endogenous CSCs following intracoronary
after MI in pigs. (A) GFPneg, c-kitpos (red) endogenous CSCs in the
myocardium. Nuclei are stained by DAPI in blue. (B) The number
heterologous HLA non-matched allogeneic CSC treatment. *P b 0.05
cardiomyocytes (red, MHC) in the infarct region, 3 weeks following h
are stained by DAPI in blue. (D) New BrdUpos myocyte formation s
allogeneic CSC treatment. *P b 0.05 vs. CTRL.
*Adapted from “Ellison et al. J Cardiovasc Transl Res. 2012;5:667–7either MHC-II locus or the co-activator molecules CD40, CD80,
CD86, ICOS-l, and express low levels of MHC-I antigens. They
also have strong immunomodulatory properties in vitro when
tested in the mixed lymphocyte reaction with high expression
of PD-L1/programmed cell death-1 [unpublished]. We there-
fore expected the cloned in vitro expanded cells to survive
long enough in the allogeneic host to produce their paracrine
effect before being eliminated by the host immune system.
Allogeneic, non-matched, cloned male EGFP-transduced
porcine eCSCs, were administered intracoronary in white
Yorkshire female pigs, 30 min after MI and coronary
reperfusion (Ellison et al., 2009). Pig serum was injected
to control pigs after MI (CTRL). The cells or sera were
injected through a percutaneous catheter into the anterior
descending coronary artery just below the site of balloon
occlusion used to produce the AMI. We found a high degree
of EGFPpos/c-kitpos heterologous HLA non-matched allogeneic
porcine CSCs nesting in the damaged pig myocardium at
30 min through to 1 day after MI. At 3 weeks post-AMI, all the
injected allogeneic cells had disappeared from the myocardi-
um and peripheral tissues (i.e. spleen). There was significant
activation of the endogenous GFPneg c-kitpos CSCs (eCSCs)
following allogeneic CSC treatment (Fig. 6), so that by
3 weeks after MI, there was increased autologous new CM
and capillary formation, which was not evident in the control
hearts (Fig. 6). Moreover, the c-kitpos heterologous HLA
non-matched allogeneic CSCs preserved myocardial wall
structure and attenuated remodelling by reducing myocyte
hypertrophy, apoptosis and scar formation (fibrosis) (Ellison et
al., 2009). In summary, intracoronary injection of allogeneicinjection of c-kitpos HLA non-matched allogeneic porcine CSCs,
3 week-old infarcted region of the allogeneic treated porcine
of c-kitpos endogenous CSCs significantly increased following
vs. CTRL. (C) Regenerating band of newly formed BrdUpos (green)
eterologous HLA non-matched allogeneic CSC treatment. Nuclei
ignificantly increased following heterologous HLA non-matched
7”.
628 B. Nadal-Ginard et al.CSCs in a clinically relevant MI model activates the eCSCs
resulting in improved myocardial cell survival, function,
remodelling and regeneration.
A possible risk of using large numbers of in vitro
expanded autologous CSCs is the appearance of transformed
cells with the potential to form abnormal growths. This risk
is practically eliminated by the use of allogeneic cells, with
a different HLA allele from the recipient, because without
immunosuppression all the allogeneic cells get eliminated
by the immune system. Claims that some of the
transplanted allogeneic cells have a long term survival in
the host, have not been reproduced or thoroughly docu-
mented (Malliaras et al., 2012; Quevedo et al., 2009; Huang
et al., 2010). If such survival would prove to be correct,
many of the immunology concepts, which have been the
basis of transplant biology until now, will need to be
revised. In this regard, it is worth noting that in mammals,
neoplasias as not transplantable to individuals with a
different HLA or MHC haplotype (Welsh, 2011). The only
exceptions to this general rule, as far as we are aware, are
the case of the oral tumours in the Tasmanian devil, where
the reason for the transplantability is under investigation
(Siddle et al., 2013). The only other demonstrated cases of
long term persistence of cells of a different HLA type in the
human are those cases of mothers with microchimerism of
cells from her male progeny in different tissues established
during pregnancy and persistent thereafter (Bianchi et al.,
1996). Whether this microchimerism is causing some of the
autoimmune diseases in these women is a matter of dispute.
Furthermore, despite thorough pathological examination
and contrary to many iPS- and ECS-derived cell lines, the
adult tissue-specific eCSCs have demonstrated a
non-existent capacity to form tumours and/or teratomas
in syngeneic and immunodefficient animals (our unpub-
lished data and Chong et al., 2011).
Allogeneic CSC therapy is conceptually and practically
different from any presently in clinical use. The proposed
cell therapy is only a different form of growth factor therapy
able to deliver a more complex mixture of growth factors
than our present knowledge permits us to prepare. The
factors produced by the allogeneic cells are designed to
stimulate the endogenous stem cells of the target tissue but
the transplanted cells themselves survive only transiently
and do not directly participate in the production of progeny
that contributes to the regenerated tissue. Thus, although
the therapeutic cells are allogeneic, the regenerative
response is completely autologous because it is carried out
by the host CSCs. However, it is clear that despite the clear
potential value of such therapy it remains to be yet properly
demonstrated endogenous CSC activation is the main
mechanism underlying the effect of allogeneic CSC trans-
plantation. To this aim further experiments and a better
understanding of the regulatory circuits governing activa-
tion, proliferation and differentiation of eCSCs are indeed
mandatory.
It is worth noting that it has been demonstrated that the
loss of regenerative potential of chronic decompensated
human heart is related to aging of CSC (Urbanek et al.,
2005). We have found that in vivo CSCs are very susceptible
to this aging process (Torella et al. 2004). Indeed, in the
cohort of patients most likely candidates for autologous
hCSC regenerative therapy, N=50% of their CSCs can besenescent and unable to participate in the regenerative
process (Urbanek et al., 2005). For that reason, it is also
imperative to determine whether the regenerative potential
of a particular CSC population in the different pathologies
leading to a decompensated heart is determined exclusively
by the number of non-senescent CSCs or whether the quality
of those that remain functional is also suboptimal because it
has deteriorated in response to the stress. In this setting it is
important to dissect the factors responsible for CSC aging
and to determine whether the aged cells can be “rejuve-
nated” and co-axed to re-enter the cell cycle and returned
to the functional pool. Obtaining specific answers to these
un-addressed issues will clearly have an impact on the
eventual clinical success of the above-described cell-free
regenerative approaches.Summary and conclusions
The adult heart harbours a regenerative multipotent cell
population composed by endogenous cardiac stem progen-
itor cells (eCSCs) and mammalian, including human,
cardiomyocytes are replaced throughout adulthood. That
these CSCs are necessary and sufficient for myocardial cell
homeostasis throughout live and to regenerate diffuse and
segmental myocardial damage represents a paradigm shift
in cardiovascular biology. The presence of this regenerative
agent within the adult heart supports the view that in
the near future it should be possible to replace cell
transplantation-basedmyocardial regeneration protocols with
an “off-the-shelf”, readily available, unlimited and effective
regenerative/reparative therapy based on specific growth
factor administration, the paracrine effect of allogeneic CSC
transplantation or a combination of both approaches.Acknowledgments
This work was supported by grants from CARE-MI FP7 (Health-F5-
2010-242038), Endostem FP7 (Health F5-2010-241440) large
scale collaborative projects, FIRB-Futuro-in-Ricerca (RBFR081CCS,
RBFR12I3KA), and Italian Ministry of Health (GR-2008-1142673, GR-
2010-2318945).
References
Abdel-Latif, A., et al., 2007. Adult bone marrow-derived cells for
cardiac repair: a systematic review and meta-analysis. Arch.
Intern. Med. 167, 989–997.
Anversa, P., Kajstura, J., 1998. Ventricular myocytes are not
terminally differentiated in the adult mammalian heart. Circ.
Res. 83, 1–14.
Anversa, P., et al., 2002. Myocyte renewal and ventricular
remodelling. Nature 415, 240–243.
Badylak, S.F., et al., 2012. Engineered whole organs and complex
tissues. Lancet 379, 943–952.
Beltrami, A.P., et al., 2001. Evidence that human cardiac myocytes
divide after myocardial infarction. N. Engl. J. Med. 344,
1750–1757.
Beltrami, A.P., et al., 2003. Adult cardiac stem cells are multipotent
and support myocardial regeneration. Cell 114, 763–776.
Bergmann, O., et al., 2009. Evidence for cardiomyocyte renewal in
humans. Science 324, 98–102.
629The cardiac stem cell compartmentBersell, K., et al., 2009. Neuregulin1/ErbB4 signaling induces
cardiomyocyte proliferation and repair of heart injury. Cell
138, 257–270.
Bianchi, D.W., et al., 1996. Male fetal progenitor cells persist in
maternal blood for as long as 27 years postpartum. Proc. Natl.
Acad. Sci. U. S. A. 93, 705–708.
Bolli, R., et al., 2011. Cardiac stem cells in patients with ischaemic
cardiomyopathy (SCIPIO): initial results of a randomised phase 1
trial. Lancet 378, 1847–1857.
Boström, P., et al., 2010. C/EBPβ controls exercise-induced cardiac
growth and protects against pathological cardiac remodeling.
Cell 143, 1072–1083.
Brown, M.S., et al., 1992. Koch's postulates for cholesterol. Cell 71,
187–188.
Buckingham, M., et al., 2008. Skeletal muscle stem cells. Curr.
Opin. Genet. Dev. 18, 330–336.
Chien, K.R., 2000. Meeting Koch's postulates for calcium signaling in
cardiac hypertrophy. J. Clin. Invest. 105, 1339–1342.
Chien, K.R., et al., 2002. Converging pathways and principles
in heart development and disease: CV@CSH. Cell 110,
153–162.
Chong, J.J., et al., 2011. Adult cardiac-resident MSC-like stem cells
with a proepicardial origin. Cell Stem Cell 9, 527–540.
Dauwe, D.F., et al., 2011. Stem cell therapy for the treatment of
myocardial infarction. Curr. Pharm. Des. 17, 3328–3340.
Dong, F., et al., 2012. Myocardial CXCR4 expression is required for
mesenchymal stem cell mediated repair following acute
myocardial infarction. Circulation 126, 314–324.
Eisenberg, C.A., et al., 2006. Bone marrow cells transdifferentiate
to cardiomyocytes when introduced into the embryonic heart.
Stem Cells 24, 1236–1245.
Ellison, G.M., et al., 2007a. Acute beta-adrenergic overload
produces myocyte damage through calcium leakage from the
ryanodine receptor 2 but spares cardiac stem cells. J. Biol.
Chem. 282, 11397–11409.
Ellison, G.M., et al., 2007b. Myocyte death and renewal: modern
concepts of cardiac cellular homeostasis. Nat. Clin. Pract.
Cardiovasc. Med. 4 (Suppl. 1), S52–S59.
Ellison, G.M., et al., 2009. Use of heterologous non-matched
Cardiac Stem Cells (CSCs) without immunosuppression as an
effective regenerating agent in a porcine model of acute
myocardial infarction. Eur. Heart J. 30, 495 (Abstract
Supplement).
Ellison, G.M., et al., 2010. Cardiac stem and progenitor cell
identification: different markers for the same cell? Front. Biosci.
2, 641–652.
Ellison, G.M., et al., 2011. Endogenous cardiac stem cell activation
by insulin-like growth factor-1/hepatocyte growth factor
intracoronary injection fosters survival and regeneration of the
infarcted pig heart. J. Am. Coll. Cardiol. 58, 977–986.
Ellison, G.M., et al., 2012. Physiological cardiac remodelling in
response to endurance exercise training: cellular and molecular
mechanisms. Heart 98, 5–10.
Ellison, G.M., et al., 2013. Adult c-kitpos cardiac stem cells are
necessary and sufficient for functional cardiac regeneration and
repair. Cell 154, 827–842.
Evans, M.J., et al., 1981. Establishment in culture of pluripotential
cells from mouse embryos. Nature 292, 154–156.
Fuchs, E., 2009. The tortoise and the hair: slow-cycling cells in the
stem cell race. Cell 137, 811–819.
Gnecchi, M., et al., 2008. Paracrine mechanisms in adult stem cell
signaling and therapy. Circ. Res. 103, 1204–1219.
Hatzistergos, K.E., et al., 2010. Bone marrow mesenchymal stem
cells stimulate cardiac stem cell proliferation and differentiation.
Circ. Res. 107, 913–922.
Hofmann, M., et al., 2005. Monitoring of bone marrow cell homing
into the infarcted human myocardium. Circulation 111,
2198–2202.Hsieh, P.C., et al., 2007. Evidence from a genetic fate-mapping
study that stem cells refresh adult mammalian cardiomyocytes
after injury. Nat. Med. 13, 970–974.
Huang, X.P., et al., 2010. Differentiation of allogeneic mesenchymal
stem cells induces immunogenicity and limits their long-term
benefits for myocardial repair. Circulation 122, 2419–2429.
Hunter, J.J., et al., 1999. Signaling pathways for cardiac hypertro-
phy and failure. N. Engl. J. Med. 341, 1276–1283.
Jayawardena, T.M., et al., 2012. MicroRNA-mediated in vitro and in
vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes.
Circ. Res. 110, 1465–1473.
Jessup, M., Brozena, S., 2003. Heart failure. N. Engl. J. Med. 348,
2007–2018.
Kahan, B.D., 2011. Fifty years in the vineyard of transplantation:
looking back. Transplant. Proc. 43, 2853–2859.
Kajstura, J., et al., 2010. Myocyte turnover in the aging human
heart. Circ. Res. 107, 1374–1386.
Kajstura, J., et al., 2012. Cardiomyogenesis in the aging and failing
human heart. Circulation 126, 1869–1881.
Kawaguchi, N., et al., 2010. c-kitpos GATA-4 high rat cardiac stem
cells foster adult cardiomyocyte survival through IGF-1 paracrine
signalling. PLoS One 5, e14297.
Kikuchi, K., et al., 2012. Cardiac regenerative capacity and
mechanisms. Annu. Rev. Cell Dev. Biol. 28, 719–741.
Kopp, J.L., et al., 2011. Progenitor cell domains in the developing
and adult pancreas. Cell Cycle 10, 1921–1927.
Kotton, D.N., 2012. Next generation regeneration: the hope and
hype of lung stem cell research. Am. J. Respir. Crit. Care Med.
(Apr 19).
Koudstaal, S., et al., 2014. Sustained delivery of insulin-like growth
factor-1/hepatocyte growth factor stimulates endogenous
cardiac repair in the chronic infarcted pig heart. J. Cardiovasc.
Transl. Res. 7, 232–241.
Kühn, B., et al., 2007. Periostin induces proliferation of differen-
tiated cardiomyocytes and promotes cardiac repair. Nat. Med.
13, 962–969.
Laflamme, M.A., et al., 2011. Heart regeneration. Nature 473, 326–335.
Latil, M., et al., 2012. Skeletal muscle stem cells adopt a dormant
cell state post mortem and retain regenerative capacity. Nat.
Commun. 3, 903.
Laugwitz, K.L., et al., 2005. Postnatal isl1+ cardioblasts enter
fully differentiated cardiomyocyte lineages. Nature 433,
647–653.
Loffredo, F.S., et al., 2011. Bone marrow-derived cell therapy
stimulates endogenous cardiomyocyte progenitors and promotes
cardiac repair. Cell Stem Cell 8, 389–398.
MacLellan, W.R., et al., 2005. Overlapping roles of pocket proteins
in the myocardium are unmasked by germ line deletion of
p130 plus heart-specific deletion of Rb. Mol. Cell. Biol. 25,
2486–2497.
Makkar, R.R., et al., 2012. Intracoronary cardiosphere-derived cells
for heart regeneration after myocardial infarction (CADUCEUS):
a prospective, randomised phase 1 trial. Lancet 379, 895–904.
Malliaras, K., et al., 2012. Safety and efficacy of allogeneic cell
therapy in infarcted rats transplanted with mismatched
cardiosphere-derived cells. Circulation 125, 100–112.
Malliaras, K., et al., 2013. Cardiomyocyte proliferation and
progenitor cell recruitment underlie therapeutic regeneration
after myocardial infarction in the adult mouse heart. EMBO Mol.
Med. 5, 191–209.
Martin, C.M., et al., 2004. Persistent expression of the ATP-binding
cassette transporter, Abcg2, identifies cardiac SP cells in the
developing and adult heart. Dev. Biol. 265, 262–275.
Matsuura, K., et al., 2004. Adult cardiac Sca-1-positive cells
differentiate into beating cardiomyocytes. J. Biol. Chem. 279,
11384–11391.
Mercier, F.E., et al., 2011. The bone marrow at the crossroads of
blood and immunity. Nat. Rev. Immunol. 12, 49–60.
630 B. Nadal-Ginard et al.Messina, E., et al., 2004. Isolation and expansion of adult cardiac
stem cells from human and murine heart. Circ. Res. 95,
911–921.
Moretti, A., et al., 2006. Multipotent embryonic isl1+ progenitor
cells lead to cardiac, smooth muscle, and endothelial cell
diversification. Cell 127, 1151–1165.
Murry, C.E., et al., 2008. Differentiation of embryonic stem cells to
clinically relevant populations: lessons from embryonic develop-
ment. Cell 132, 661–680.
Nadal-Ginard, B., 1978. Commitment, fusion and biochemical
differentiation of a myogenic cell line in the absence of DNA
synthesis. Cell 15, 855–864.
Nadal-Ginard, B., et al., 2003. Myocyte death, growth, and
regeneration in cardiac hypertrophy and failure. Circ. Res. 92,
139–150.
Oh, H., et al., 2001. Telomerase reverse transcriptase promotes
cardiac muscle cell proliferation, hypertrophy, and survival.
Proc. Natl. Acad. Sci. U. S. A. 98, 10308–10313.
Oh, H., et al., 2003. Cardiac progenitor cells from adult myocardium:
homing, differentiation, and fusion after infarction. Proc. Natl.
Acad. Sci. U. S. A. 100, 12313–12318.
Orlic, D., et al., 2001. Bone marrow cells regenerate infarcted
myocardium. Nature 410, 701–705.
Porrello, E.R., et al., 2011. Transient regenerative potential of the
neonatal mouse heart. Science 331, 1078–1080.
Qian, L., et al., 2012. In vivo reprogramming of murine cardiac
fibroblasts into induced cardiomyocytes. Nature 485, 593–598.
Quaini, F., et al., 2002. Chimerism of the transplanted heart. N.
Engl. J. Med. 346, 5–15.
Quevedo, H.C., et al., 2009. Allogeneic mesenchymal stem cells
restore cardiac function in chronic ischemic cardiomyopathy via
trilineage differentiating capacity. Proc. Natl. Acad. Sci. U. S. A.
106, 14022–14027.
Ranganath, S.H., et al., 2012. Harnessing the mesenchymal stem
cell secretome for the treatment of cardiovascular disease. Cell
Stem Cell 10 (3), 244–258.
Rasmussen, T.L., et al., 2011. Getting to the heart of myocardial
stem cells and cell therapy. Circulation 123, 1771–1779.
Reule, S., et al., 2011. Kidney regeneration and resident stem cells.
Organogenesis 7, 135–139.
Robinton, D.A., et al., 2012. The promise of induced pluripotent
stem cells in research and therapy. Nature 481, 295–305.
Roger, V.L., et al., 2012. American Heart Association Statistics
Committee and Stroke Statistics Subcommittee. Heart disease
and stroke statistics–2012 update: a report from the American
Heart Association. Circulation 125, e2–e220.
Rountree, C.B., et al., 2012. Stem cells in liver diseases and cancer:
recent advances on the path to new therapies. Hepatology 55,
298–306.
Rumyantsev, P.P., 1991. In: Carlson, B.M. (Ed.), Reproduction of
growth and hyperplasia of cardiac muscle cells., 3. Harwood
Academic Publishers, Chur, Switzerland, pp. 1–371.
Sampaolesi, M., et al., 2005. Cell therapy of primary myopathies.
Arch. Ital. Biol. 143, 235–242.
Schneider, J.W., et al., 1994. Reversal of terminal differentiation
mediated by p107 in Rb−/− muscle cells. Science 264,
1467–1471.
Senyo, S.E., et al., 2013. Mammalian heart renewal by pre-existing
cardiomyocytes. Nature 493, 433–436.Siddle, H.V., et al., 2013. Reversible epigenetic down-regulation of
MHC molecules by devil facial tumour disease illustrates immune
escape by a contagious cancer. PNAS 110, 5103–5108.
Simons, B.D., et al., 2011. Stem cell self-renewal in intestinal crypt.
Exp. Cell Res. 317, 2719–2724.
Smart, N., et al., 2011. De novo cardiomyocytes from within the
activated adult heart after injury. Nature 474, 640–644.
Smith, R.R., et al., 2007. Regenerative potential of cardiosphere-
derived cells expanded from percutaneous endomyocardial
biopsy specimens. Circulation 115, 896–908.
Song, K., et al., 2012. Heart repair by reprogramming non-myocytes
with cardiac transcription factors. Nature 485, 599–604.
Soonpaa, M.H., et al., 1998. Survey of studies examining mammalian
cardiomyocyte DNA synthesis. Circ. Res. 83, 15–26.
Srivastava, D., et al., 2006. Potential of stem-cell-based therapies
for heart disease. Nature 441, 1097–1099.
Suh, H., et al., 2009. Signaling in adult neurogenesis. Annu. Rev.
Cell Dev. Biol. 25, 253–275.
Takahashi, K., et al., 2006. Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined
factors. Cell 126, 663–676.
Takahashi, K., et al., 2007. Induction of pluripotent stem cells from
adult human fibroblasts by defined factors. Cell 131, 861–872.
Tam, S.K., et al., 1995. Cardiac myocyte terminal differentiation.
Potential for cardiac regeneration. Ann. N. Y. Acad. Sci. 752, 72–79.
Terzic, A., et al., 2010. Regenerative medicine advancing health
care 2020. J. Am. Coll. Cardiol. 55, 2254–2257.
Thomson, J.A., et al., 1998. Embryonic stem cell lines derived from
human blastocysts. Science 282, 1145–1147.
Torella, D., Rota, M., Nurzynska, D., Musso, E., Monsen, A., Shiraishi,
I., Zias, E., Walsh, K., Rosenzweig, A., Sussman, M.A., Urbanek,
K., Nadal-Ginard, B., Kajstura, J., Anversa, P., Leri, A., 2004.
Cardiac stem cell and myocyte aging, heart failure, and insulin-
like growth factor-1 overexpression. Circ Res. 94, 514–524.
Torella, D., et al., 2007. Resident cardiac stem cells. Cell. Mol. Life
Sci. 64, 661–673.
Uchida, S., et al., 2013. Sca1-derived cells are a source of myocardial
renewal in the murine adult heart. Stem Cell Rep. 1, 397–410.
Urbanek, K., et al., 2003. Intense myocyte formation from cardiac
stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci.
U. S. A. 100, 10440–10445.
Urbanek, K., et al., 2005. Myocardial regeneration by activation of
multipotent cardiac stem cells in ischemic heart failure. Proc.
Natl. Acad. Sci. U. S. A. 102, 8692–8697.
Waring, C.D., Vicinanza, C., Papalamprou, A., Smith, A.J.,
Purushothaman, S., Goldspink, D.F., Nadal-Ginard, B., Torella,
D., Ellison, G.M., 2012. The adult heart responds to increased
workload with physiologic hypertrophy, cardiac stem cell
activation, and new myocyte formation. Eur Heart J. (in press)
[Epub ahead of print] PMID: 23100284.
Welsh, J.S., 2011. Contagious cancer. Oncologist 16, 1–4.
Yamanaka, S., 2007. Strategies and new developments in the
generation of patient-specific pluripotent stem cells. Cell Stem
Cell 1, 39–49.
Yoshida, Y., et al., 2010. Recent stem cell advances: induced
pluripotent stem cells for disease modeling and stem cell-based
regeneration. Circulation 122, 80–87.
Zhang, R., et al., 2013. In vivo cardiac reprogramming contributes
to zebrafish heart regeneration. Nature 498, 497–501.
